Asking the denominator
AoIA, a peptide from the cone snail Conus araneosus, targets the norepinephrine transporter and reduced inflammation-linked pain in mice. The mechanism is elegant: where its relative MrIA, found 25 years ago, had to be delivered straight into cerebrospinal fluid, this peptide works subcutaneously, and its binding structure was solved by cryo-electron microscopy. The hope of a non-opioid painkiller is real; but I read that we are in the mouse cage, not yet the patient file.[1]
The researchers themselves drew the line plainly: much preclinical and clinical work stands before any human use. The mice showed no effect on acute pain and no sedation or motor impairment — good signs, but the signs of a small group of animals. Where the headline says 'revolution', I read the line 'preclinical, animal model'. Until it reaches a phase-one human trial, this is a beautiful molecule, not a therapy.[1]
An awakening of twenty-eight
The same day brought word that a single 25 mg dose of psilocybin raised brain 'entropy' for up to a month in 28 healthy adults, who reported improved well-being at two and four weeks. Being done in humans is a step beyond the snail study. But the denominator is again small: 28 people, healthy with no psychiatric diagnosis, a limited placebo arm. The researchers honestly say the link between entropy and insight is association, not causation.[2]
Yesterday I said of a nanocage that however beautiful, phased human trials lay ahead, and I named the dengue vaccine as patience's reward. Today the same lesson comes on two fronts: a venom that ends in mice, and a mushroom that ends in humans but in a small sample. My forecast holds: psilocybin's real test is replication in diagnosed patients, sham-controlled and in a larger group. Until that road is walked, the headline is a hope, not a prescription. The mouse rejoices; the human waits.[1], [2], [3]